Desmopressin Side Effects: Safety Signals and Warnings
Desmopressin safety concerns are compound-specific. The main listed side effects are Headache, Nasal congestion (intranasal), and Nausea. The main warning signals are Hyponatremia/water intoxication - restrict fluid intake; monitor serum sodium, Contraindicated in habitual polydipsia, and Nasal formulation affected by nasal congestion, rhinitis - switch to oral if unreliable absorption.
Direct Answer
Desmopressin (DDAVP) is FDA-approved for central diabetes insipidus, primary nocturnal enuresis, and hemostasis in mild hemophilia A/von Willebrand disease type I - a broad indication profile reflecting 40+ years of clinical evidence. Its selectivity for V2 receptors over V1 receptors (versus natural vasopressin) makes it the preferred ADH analog for antidiuretic applications. A highly validated, multi-indication peptide drug.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- Central diabetes insipidus, nocturnal enuresis, hemostasis in mild hemophilia A/vWD type I, ADH receptor research
Reported Side Effects
- Headache
- Nasal congestion (intranasal)
- Nausea
- Abdominal cramps
- Facial flushing
- Hyponatremia
Warnings
- Hyponatremia/water intoxication - restrict fluid intake; monitor serum sodium
- Contraindicated in habitual polydipsia
- Nasal formulation affected by nasal congestion, rhinitis - switch to oral if unreliable absorption
- Use caution in patients with cardiovascular disease or conditions predisposing to fluid/electrolyte imbalance
- Tachyphylaxis possible with repeated dosing for hemostatic use
Known or Plausible Interactions
- NSAIDs, SSRIs, TCAs (increase risk of hyponatremia)
- Chlorpropamide (potentiates antidiuretic effect)
- Loperamide (increases desmopressin absorption)
- Lithium (may reduce antidiuretic response)
Regulatory Context
FDA-approved for central diabetes insipidus, primary nocturnal enuresis, hemophilia A, and type 1 von Willebrand disease. Multiple formulations available by prescription. Marketed by various manufacturers including Ferring.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Central Diabetes Insipidus (Level A), Nocturnal Enuresis (Level A), Hemophilia A / vWD Bleeding (Level A), and Hyponatremia Risk (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Desmopressin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/desmopressin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.